BioDelivery Sciences to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

BioDelivery Sciences International, Inc. (Nasdaq: BDSI), today announced that Mark A. Sirgo, Pharm.D., President and Chief Executive Officer, will present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference.

Dr. Sirgo’s presentation will take place at 9:30 a.m. EDT on Wednesday, August 5, 2009 at the Millennium Broadway Hotel in New York. A live webcast can be accessed from the BMO Capital Markets website at www.bmocm.com.

Dr. Sirgo will be discussing the recent FDA approval and market opportunity for BDSI’s first product, ONSOLIS™ (fentanyl buccal soluble film). Dr. Sirgo will also review the status of the company’s product pipeline, including BEMA®Buprenorphine and Bioral® Amphotericin B and expectations for 2009 and beyond.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ:BDSI - News) is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner, and commercialize new products using proven therapeutics. BDSI’s pain franchise utilizes the Company’s patented BEMA® buccal soluble film technology and currently consists of: ONSOLIS (fentanyl buccal soluble film) a treatment for “breakthrough” pain in opioid tolerant patients with cancer, and BEMA Buprenorphine, a second analgesic in development with at least one potential target indication for the treatment of moderate to severe pain. The company is working with its BEMA and Bioral technologies on products targeted at conditions common to oncology and surgical patients such as pain and infections. The company headquarters is located in Raleigh, North Carolina, and its principal laboratory is located in Newark, New Jersey. For more information please visit www.biodeliverysciences.com.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).